Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer 
    		2015 NCCN Annual Conference
    	
    	
    	
    
        Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.
    
    
    
    
       
       
    		Mario E. Lacouture, MD
		
		
        
		
		
		
		Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.
			
			
     	
    
       
       
    		Mary Lou Smith, JD, MBA
		
		
        
		
		
		
		Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
			
			
     	
    
       
       
    		Gregory A. Otterson, MD
		
		
        
		
		
		
		Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.
			
			
     	
    
       
       
    		Kenneth C. Anderson, MD
		
		
        
		
		
		
		Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
			
			
     	
    
       
       
    		Jerald P. Radich, MD
		
		
        
		
		
		
		Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months will ultimately prove useful.